Panelists discuss how selecting and optimizing Janus kinase (JAK) inhibitor therapy in myelofibrosis involves personalizing treatment based on patient risk factors, comorbidities, and preferences ...

The use of JAK vs TNF inhibitors shows no significant increase in the incidence of major adverse cardiovascular events in ...

Janus kinase (JAK) inhibitors led to improvement of uveitis in approximately half of pediatric patients previously treated with disease-modifying antirheumatic drugs (DMARDs) in a case series.

Citation: JAK inhibitors show no increased cardiovascular risk in rheumatoid arthritis patients, large international study finds (2025, April 30) retrieved 3 May 2025 from https://medicalxpress ...

In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for ...

Upadacitinib will face two main JAK inhibitor competitors – Eli Lilly’s Olumiant and Pfizer’s Xeljanz. Despite excitement surrounding the class, though, these treatments all face a complex ...

A panelist discusses how the comprehensive ADVANCES safety monitoring system data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) revealed distinct infection risk ...

New study links prior VTE, diabetes, recent hospitalization, and JAK inhibitor use with elevated thromboembolism risk in ...

"We see a number of examples with the IL-23 inhibitors that ... Currently approved therapies for alopecia areata are all JAK inhibitors and carry boxed warning labels, King noted.

Concerns have arisen over JAK inhibitors' cardiovascular safety relative to TNF inhibitors and other biologic agents for rheumatoid arthritis. Registry data from more than 50,000 European patients ...